NPPA Approves 30% Trade-Margin Cap on Cancer Medicines in Principle

On 8 October 2026, the National Pharmaceutical Pricing Authority (NPPA) approved in principle a 30% trade-margin cap, linked to the Maximum Retail Price (MRP), for identified non-scheduled anti-cancer medicines. The only source for this event is a GKToday report dated 9 October 2026. As of 10 October 2026 the decision is an in-principle approval, not a notified rule. The covered list is not yet final and the formal notification has not been reported.

What was decided and when

The approval came at the NPPA's 151st meeting on 8 October 2026. The GKToday report was published a day later, so 8 October is the event date and 9 October is the publication date.

• Decision: in-principle approval of a 30% trade-margin cap on identified non-scheduled anti-cancer medicines, based on MRP.
• Projected effect: price reductions of 20% to 70% and estimated patient savings of about ₹2,500 crore a year. These are projections reported by the source, not measured outcomes.
• Proposed coverage: 110 anti-cancer drugs, including 35 patented medicines.
• Supply: manufacturers of the covered medicines have been directed to maintain current production levels.

Status as of 10 October 2026

Completed

The NPPA's in-principle approval at its 151st meeting is complete.

Still pending

An expert committee under the Directorate General of Health Services (DGHS) is to finalise the list of 110 drugs. After that, the NPPA is to issue a formal notification. The evidence gives no date for either step, so the cap should not be treated as in force yet.

Why the cap is proposed

The NPPA's analysis, as reported, found that non-scheduled anti-cancer medicines had an average trade markup of about 170%, with some markups reaching 700%. A trade-margin cap targets this markup in the distribution chain between the manufacturer and the patient, rather than fixing a ceiling price for each drug. The source does not explain the exact formula for applying the 30% figure to MRP, so that detail should be checked in the final notification.

Background: how drug prices are regulated in India

Scheduled and non-scheduled formulations

The Drugs (Prices Control) Order, 2013 (DPCO, 2013) is the framework for medicine price control. A 2021 Press Information Bureau (PIB) release says it follows the National Pharmaceutical Pricing Policy, 2012. The NPPA works under the Department of Pharmaceuticals and fixes ceiling prices for scheduled drugs listed in the order's first schedule. GKToday links scheduled formulations to the National List of Essential Medicines.

Non-scheduled drugs do not get a fixed ceiling price. Instead, the NPPA monitors them so that their MRP does not rise by more than 10% over the preceding twelve months.

The earlier cap on 42 drugs

Trade-margin capping on anti-cancer drugs is not new. GKToday reports that in February 2019 the government capped trade margins on 42 selected non-scheduled anti-cancer drugs, covering 526 brands and saving ₹984 crore a year. A 2021 PIB release calls this the 'Trade Margin Rationalization (TMR)' approach and reports MRP reductions of up to 90% for those 526 brands. PIB's table lists the 42 drugs under 2018-19. The two sources use different savings framings, so the ₹984 crore figure rests on GKToday alone.

2019 cap compared with the 2026 proposal

Exam-relevant points

• The NPPA is the authority that administers price controls under DPCO, 2013.
• Scheduled formulations have ceiling prices. Non-scheduled formulations are monitored, with a 10% annual limit on MRP increases.
• This proposal is a trade-margin cap for identified non-scheduled anti-cancer drugs, not a ceiling-price fixation.
• Key numbers: 30% cap, 151st meeting, 8 October 2026, 110 drugs, 35 patented medicines, 42 drugs and 526 brands in the earlier measure.

This article does not predict whether any of these points will appear in an exam. It only sets out the supported facts.

Evidence limits

The 2026 decision is reported by a single secondary source. The supplied evidence contains no NPPA or PIB statement on it. The 2021 PIB release supports only the background on the earlier measure and the pricing framework. The headline wording says the 'government' approved the cap, but the source attributes the decision to the NPPA. The final drug list, the implementation date and the exact calculation of the cap remain unconfirmed.

FAQ

Is the 30% trade-margin cap already in force?

Not according to the evidence. It has in-principle approval only. The DGHS expert committee must finalise the list, and the NPPA must then issue a formal notification.

Does it apply to all cancer medicines?

No. It is proposed for identified non-scheduled anti-cancer medicines. The proposed list has 110 drugs, including 35 patented ones, and is subject to finalisation.

What is the difference between scheduled and non-scheduled drugs?

Scheduled drugs are subject to NPPA-fixed ceiling prices under DPCO, 2013. Non-scheduled drugs are monitored, and their MRP generally cannot rise by more than 10% in a year.